Cantor Fitzgerald Forecasts AUPH FY2026 Earnings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Aurinia Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer expects that the biotechnology company will post earnings per share of $0.64 for the year. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share.

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Up 0.1%

Shares of Aurinia Pharmaceuticals stock opened at $8.15 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals has a 52-week low of $5.15 and a 52-week high of $10.67. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -54.33 and a beta of 1.15. The company’s 50 day moving average price is $7.95 and its 200-day moving average price is $8.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. The firm had revenue of $62.47 million for the quarter, compared to analysts’ expectations of $61.06 million.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tang Capital Management LLC raised its holdings in Aurinia Pharmaceuticals by 16.6% in the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after purchasing an additional 1,200,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in Aurinia Pharmaceuticals by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock worth $15,535,000 after purchasing an additional 112,113 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Aurinia Pharmaceuticals by 10.2% in the 4th quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company’s stock worth $13,401,000 after purchasing an additional 138,054 shares in the last quarter. Nuveen LLC bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth $10,014,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in Aurinia Pharmaceuticals in the 4th quarter worth $9,662,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.